Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;22(12):1650-1651.
doi: 10.1016/S1473-3099(22)00522-9. Epub 2022 Aug 24.

Early oral antiviral use in patients hospitalised with COVID-19

Dorota Zarębska-Michaluk  1 , Robert Flisiak  2
Affiliations
Comment

Early oral antiviral use in patients hospitalised with COVID-19

Dorota Zarębska-Michaluk et al. Lancet Infect Dis. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DZ-M reports advisory and lecture honoraria from MSD and Gilead. RF reports grants and advisory and lecture honoraria from MSD, Gilead, and Roche.

Comment on

References

    1. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: an observational study. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00507-2. published online Aug 24. - DOI - PMC - PubMed
    1. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antiviral Res. 2022;198 - PMC - PubMed
    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520. - PMC - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–1408. - PMC - PubMed
    1. Arribas JR, Bhagani S, Lobo SM, et al. Randomized trial of molnupiravir or placebo in patients hospitalized with COVID-19. NEJM Evidence. 2022;1 - PubMed

Substances